506128 logo

Parnax Lab Limited Stock Price

BSE:506128 Community·₹1.3b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

506128 Share Price Performance

₹113.45
-60.60 (-34.82%)
₹113.45
-60.60 (-34.82%)
Price ₹113.45

506128 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet and slightly overvalued.

2 Risks
1 Reward

Parnax Lab Limited Key Details

₹2.1b

Revenue

₹1.2b

Cost of Revenue

₹870.4m

Gross Profit

₹760.2m

Other Expenses

₹110.3m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
9.60
42.40%
5.37%
67.0%
View Full Analysis

About 506128

Founded
1982
Employees
12
CEO
Mihir Shah
WebsiteView website
www.naxparlab.com

Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic products; herbal products; and nutraceutical products. It also provides Oral Formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provides drug identification and development services; in- and out-licensing services; and contract research and manufacturing services The company was formerly known as Krishna-Deep Trade & Investments Limited and changed its name to Parnax Lab Limited in April 2012. The company was incorporated in 1982 and is headquartered in Mumbai, India.

Recent 506128 News & Updates

Recent updates

No updates